AFT Pharma optimistic despite minor profit dip
AFT Pharma optimistic despite minor profit dip
About this video
Hartley Atkinson, CEO of AFT Pharma, discusses the company's latest half-year financial results. Hartley reports a pleasing growth trend in the business's sales across Asian and international markets, resulting in increased revenue. A significant portion of their investments in the first half was devoted to R&D, licensing new products, and promoting and marketing newly launched products.
Expanding on AFT Pharma's global expansion plans, Hartley mentions a successful growth trend in existing countries as well as entering new markets. Their product 'Maxigesic', a Paracetamol and Ibuprofen combined drug, is available in 66 countries and is set to launch in the U.S next year after FDA approval. China, as the world's second-largest pharmaceutical market, also features in the company's plans, with the successful acquisition of their first approval for 'Crusader', an antiseptic antibacterial cream, set to launch next year.
Discussing other aspects of the business, Hartley mentions solid growth in AFT Pharma's online presence via collaborations with online retailers such as Amazon and growing cross-border e-commerce in China. He also shares the company's future plans, which include focusing on internal e-commerce within China and expanding into new markets like Singapore. Hartley concludes by discussing their growth and R&D investments, maintaining their staff strength, and their intention to declare a full-year dividend for shareholders.
Find the full unedited transcript of this interview below:
0:00
Let's get company specific now, because AF two pharmaceuticals have released their half year financial results. The New Zealand based company says their sales across Asian and international markets have grown, boosting revenue, but operating profit is slightly down. CEO Dr. Harley Atkinson joins me now. Thanks so much for joining us. Just your overall take on on where your business is and run us through some of the key numbers. Yeah. Look, we were pleased basically where our aiming to grow the business. We've been investing very strongly in the first half and R&D and then licensing new products and also sales promotions and marketing promotions for newly launched products. So it was a deliberate thing to spend more in that first half. And then we relatively well button off a bit in the second half. But we got the sales growth, especially international, which is what we've been really aiming at. Yeah, well that's really interesting. You're quite strong reach. I was seeing that
0:59
magic which if you can correct me, is a bit of a paracetamol and ibuprofen combined drug. And it's in now 66 countries and will soon launch in the US. So just talk us through your global expansion plans. Yeah. Look the US is certainly a key market, being obviously the largest market in the world. But we're getting good ongoing growth in our existing countries, organic growth. And then also we're launching in new countries, which is giving us further growth, makes it itself actually as a whole family of products. So we have a tablet have like an oral liquid we're launching in Europe, an intravenous formulation, which we've launched in quite a lot of countries, including Australia, but also we're launching in the United States the start of next calendar year. And that's significant. What about your push into China and how significant that market is? I understand you've also got some other hubs in Asia, including Hong
1:59
Kong and Singapore. Yeah. Look, China clearly is the world's second largest pharmaceutical market, so it obviously has to be of interest. We were successful literally this week and getting our first approval for Crusader, which is a topical antiseptic antibacterial cream. So we'll look to launch that next calendar year into China as well. But also we do have hubs. We operate in Singapore, Hong Kong. So we have quite a big range of products in Australia, for example. And now we're spreading those out into other markets like Singapore and also Hong Kong as well. How is the online part of your business going in terms of moving into the likes of Amazon and other online retailers, and are you looking at any potential boost from Black Friday sales? Yeah, look, we obviously do do work on the online stuff as well. Which things are long term going to be important part of our business? We're getting some pretty good growth at
2:59
the moment in our China cross-border e-commerce. That'll take a while. But we are getting, you know, good growth and certainly things like, yeah, Black Friday help. But also importantly, once we have approval, like with custody within China, the actual relative size of e-commerce is much bigger going from within China than relying on cross-border. So that was another important thing. You know, literally internal cross-border and internal e-commerce in China is about 20 times bigger than cross-border. So that's something we'll be focusing on going forward as well. What sort of impact have you had since the pandemic has kind of eased in terms of potentially an impact to sales? Yeah, we we did struggle a bit internationally in the pandemic because, for example, one of our products as a hospital injectable analgesic, you know, and doctors really weren't well placed to focus on
3:58
any new products during the pandemic because obviously they were swamped with cases in their hospitals. So certainly as the pandemic ease, you know, we've seen things really pick up and it's kind of nice to see we're basically back to business as usual now, which is a lot easier during the pandemic was actually very difficult, although we did still grow okay. And in terms of some of that growth, we mentioned Asia, but I understand you're pushing into South Korea as well. So just talk us through some of that geographic expansion and where you expect to see further momentum for your products. Yeah. Look, we are covering quite a number of countries. We launched the end of last year in South Korea. That's actually gone very well. The South Koreans tend to be early adopters of products. They have that mentality and our sales are going very nicely. In South Korea. We started off with modest forecasts, but as things progressed and our licensee there had comments from doctors like they're really surprised and pleased at how well the
4:58
product was working for them. That sounds have really taken off, which is good. What? I guess your main competition and how are you and the board trying to counteract that?
5:09
Yeah. Look, in a lot of markets like the US, I guess our competition is opioid analgesics, which honestly are in our view, a real scourge. You know, literally one person in the US dies every nine minutes from opioid overdoses. So that is one of our competitors and one that we're keen to compete hard against because we believe it is better for patients and better for doctors. So you you spoke in terms of your rollout and your growth, trying to have the push geographically, but also the organic sales. What are you seeing in terms of shareholder returns? Will you be declaring a dividend for full year 24? Yeah. Look, so obviously we had the interim period and we're not declaring an interim dividend. But last year we had a maiden dividend to the full year. And certainly we see it as very important to also have a full term dividend this year as well. So we are walking that
6:08
balance between growing the business strongly. But also we do want to pay our shareholders a dividend as well. And in terms of how the company is going I mean we've been talking about a lot of talent wars, but also of course higher interest rates hurting businesses. You started as a family business. How are your staffing levels and are you looking at expansion on that front? Yeah, look, we've expanded our staff. Basically. We were probably about 100 at the end of last year. We're about 115 or something now, you know, so we are expanding staff. We do do a lot of trainings. So basically we get young people that come out of university, we take on, you know, the sort of hard yards to train them up. And we've actually been able to get staff okay, which has been really pleasing. And how much have you set aside for further R&D? Can you tell us that? Yeah. Look, we've committed to spending around 12 million a year. We've got a lot of really good R&D projects, and we are getting some additional ones.
7:08
And the foreseeable future, we still see it being about 12 million. But look, if it has to go up a little bit to 12 to 15 million, we're not particularly worried about that because we do fund it out of ongoing profits.